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Purpose: Uveal melanoma (UM) typically spreads to the liver, where it is incurable, as
there are limited therapeutic interventions available. This study aimed to standardize
laboratorymethods for generating three-dimensional (3D) spheroids usingUMcell lines
and primary UM (PUM) samples for use in drug screening.
Methods: Six UM cell lines and nine PUM, of differing genetic characteristics were
cultured in two dimensions (2D) and three dimensions. 3D spheroid formation and
growth were time monitored, and ImageJ software was used to calculate cross-
sectional areas. PUM spheroids underwent immunohistochemistry for melanoma
markers, nuclear BAP1, and cell proliferation. Chromosomal alterations in patient UM
biopsies were compared with the corresponding 3D spheroid. In vitro drug assays
testing doxorubicin and selumetinib assessed drug penetration and toxicity after 48
hours using imaging and the CellTiter-Glo 3D Cell Viability Assay.
Results: All six UM cell lines formed spheroids of varying sizes and compactness; six of
the nine PUM samples (67%) also formed spheroids, composed of MelanA+ proliferat-
ing melanocytes and admixed macrophages. PUM spheroids were genetically identical
to the original sampled tumor. In vitro drug assays showed varying penetrations into
UM cell line spheroids, with doxorubicin passing into the spheroid core and selumetinib
having an effect largely on peripheral cells. Both drugs caused a dose-dependent reduc-
tion in viability of 3D spheroid cells.
Conclusions: UM cell lines and PUM samples can successfully generate uniform 3D
spheroids. PUM spheroids retain histological and genetic characteristics of the primary
tumor. 3D spheroids are an important system for use in future high-throughput drug
testing.
Translational Relevance: The use of 3D spheroids allows early-phase drug screening
and is an important first step toward treatment personalization for UM patients.
Introduction
The increasing use of three-dimensional (3D) in
vitro cell cultures in cancer is contributing to the devel-
opment of more physiologically relevant models of
tumor biology than standard two-dimensional (2D)
cultures. 3D spheroids more closely recapitulate the
physiology of the tumor microenvironment (TME),
allowing cell-to-cell contact and cell-to-matrix synthe-
sis,1 as well as the development of oxygen/nutrient
gradients that occur across the spheroid.2 Cells remain
in different proliferative andmetabolic states within the
spheroid, as would be expected within the tumor. 2D
cultures also show artificially high levels of cell prolif-
eration that are not typically seen in patient tissues,
often resulting in enhanced drug sensitivities that are
not representative of drug efficacy in vivo.3 In contrast,
3D spheroids have been shown to convey reduced
drug sensitivities when compared with traditional 2D
systems, suggesting that they could bettermodel in vivo
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drug potencies, and this may help with testing new
anticancer strategies.4
To date, in vitro studies examining uveal melanoma
(UM) biology, such as cancer cell invasion and migra-
tion, TME signaling and crosstalk, and responses to
anticancer therapies, have generally been conducted
using 2D cultures of UM cell lines.5–7 The lack of
effective tumor treatments in metastatic UM creates
an urgent unmet need for improved cellular systems,
not only to enhance our understanding of this disease
but also to more accurately translate drug efficacy to
patients. Recent studies have profiled more complex
UM culture systems, including 3D spheroids created
from UM cell lines embedded in either collagen or
Matrigel (Corning Inc., Corning, NY)8,9; however,
the methods used by these groups and the techni-
cal challenges, such as spheroid uniformity, are not
described in great detail. Method optimization for 3D
spheroid culture and an improved understanding of the
advantages and challenges that each of these methods
offers are key to bridging the gap between 2D-cultured
monolayers, animal models, and patient clinical trials.
In this study, we provide detailed methods for culti-
vating 3D spheroids using a range of UM cell lines
and, for the first time, to the best of our knowledge,
human primary UM (PUM) samples. We describe the
UM spheroid growth, their phenotype, use in drug
screening assays, and the effect of two therapeutic
agents (doxorubicin and selumetinib) used previously




The following UM cell lines (stock passage number)
were used in the studies: 92.1 (P57), OMM2.5 (P20),
MM66 (P44), MP41 (P177), OMM1 (P+3), and
MP46 (P26).10–13 All UM cell lines were authenticated
by short tandem repeat (STR) profiling according
to published data14 or data available from Ameri-
can Type Culture Collection. Cell lines were used
within 10 passages of resuscitation and were free from
mycoplasma. Cells were maintained under standard
conditions (37°C, 5% CO2) in RPMI with Gluta-
MAX (Gibco, Thermo Fisher Scientific, Waltham,
MA) supplemented with 10% fetal calf serum (FCS;
Labtech, East Sussex, UK), hereafter referred to
as UM medium A. For all studies, UM cell lines
were harvested at ∼70% confluence with 0.05%
trypsin/ethylenediaminetetraacetic acid (EDTA),
counted and resuspended at varying cell densities
(5000, 7500, 10000 cells/well) for 3D culture, as
indicated below.
Primary UM
This study was approved by the Health Research
Authority (HRA reference: 15/SS/0097), and all UM
patients provided informed written consent for the
use of their material and data in research. Fresh
PUM specimens from patients undergoing enucleation
or local resection were obtained from the Liverpool
Ocular Oncology Biobank (LOOB) (HRA reference:
16/NW/0380). A small piece of fresh PUM tissue,
approximately 3mm3, was finely minced with a sterile
scalpel blade and digested with 500-U/ml type I colla-
genase (Sigma-Aldrich, St. Louis, MO) at 37°C for
approximately 1 hour with occasional agitation, as
previously described.15 Single cells were harvested by
centrifugation at 1800 rpm for 2 minutes and resus-
pended in primary cell culture medium, hereafter
referred to as UM medium B: α-MEM (Sigma-
Aldrich) supplemented with AmnioSelect (Metachem
Diagnostics, Northampton, UK), 10% FCS (Labtech),
2-mM l-glutamine (Sigma-Aldrich), and Gibco 1%
penicillin–streptomycin (5000 U/ml, Thermo Fisher
Scientific). Cells were maintained in a humidified
incubator (5% CO2) at 37°C and harvested at 60% to
70% confluence with 0.05% trypsin–EDTA solution
(Thermo Fisher Scientific); they were then counted and
resuspended for 3D culture at varying cell densities
(2000, 4000, 8000, or 16,000 cells/well), as indicated
below.
Spheroid Assay
UM cell lines and PUM cells were harvested as
described above and plated into ultra-low attach-
ment (ULA), 96-well, clear, round-bottomed plates
(Corning) at varying densities in 100-μl volumes of
UM medium A or medium B for cell lines and
PUM cells, respectively. Cells were imaged between
days 1 and 10 of incubation with the EVOS M5000
Imaging System (Thermo Fisher Scientific) or a Zeiss
Axio Observer Z1 microscope (Carl Zeiss Meditec,
Oberkochen, Germany).
Measurement of Spheroid Size
Spheroid images were analyzed for growth determi-
nation using ImageJ/Fiji software (National Institutes
of Health, Bethesda, MD) and an open-source macro
developed by Ivanov et al.16 The macro automated the
measurement of themaximum spheroid cross-sectional
area by converting images to black and white before
applying the Yen thresholding algorithm.17 Data were
subsequently collated and further analyzed using Excel
(Microsoft Corp., Redmond, WA) and GraphPad
Prism (GraphPad, SanDiego, CA). For both PUMand
cell lines, three to six spheroids were analyzed for each
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Table 1. Antibodies Used to Stain and Characterize Formalin-Fixed PUM Spheroids
Antibody Species Isotype Dilution Supplier
Positive Human
Control Tissue
MelanA Mouse IgG1, mouse monoclonal 1:100 Agilent Technologies (Santa
Clara, CA)
Eye containing UM
Ki67 Mouse IgG1, mouse monoclonal 1:200 Leica Biosystems (Wetzlar,
Germany)
Tonsil
BAP1 Mouse IgG1, mouse monoclonal 1:200 Santa Cruz Biotechnology
(Dallas, TX)
Pancreas




time point and, in the case of the UM cell lines, in three
separate experiments.
Immunohistochemistry
PUM spheroids were removed from the ULA plates
using a cut 200-μl pipette tip at various time points and
fixed in 10% neutral buffered formalin for 15 minutes.
Spheroids were then suspended in 2% agar before
being processed using the Bayer Tissue-Tek VIP E300
tissue processor (Bayer AG, Leverkusen, Germany).
Processed spheroids were subsequently embedded in
paraffin blocks and sectioned at 4 μm onto X-tra
adhesive slides (Leica Biosystems, Wetzlar, Germany),
for immunohistochemical (IHC) staining.
IHC staining was performed as previously
described18 using the Dako Pre-Treatment Module
and the Dako Envision FLEX kit (Agilent Technolo-
gies, SantaClara, CA), according to themanufacturer’s
instructions. Details of antibodies, antigen retrieval,
and concentrations are provided in Table 1. Positive
staining was visualized with an AEC substrate kit
(Vector Laboratories, Burlingame, CA) according to
the manufacturer’s instructions. Sections were counter-
stained with Mayer’s hematoxylin (VWR, Leighton
Buzzard, UK), dyed blue with Scott’s tap water
(Leica), and mounted using Aquatex aqueous mount-
ing medium (Sigma-Aldrich). Slides were scanned
using the Leica Aperio CS2 slide scanner at 20×
magnification.
Genetic Characteristics of UM Spheroids by
MLPA
Clinical, histopathological, and genetic informa-
tion for the PUM samples used in 3D culture was
provided by the LOOB and is shown in Table 2.
PUM spheroids were also assessed for copy number
variations (CNVs) in chromosomes 1, 3, 6, and 8q
by multiplex ligation-dependent probe amplification
(MLPA). In brief, three PUM spheroids from each
patient were pooled and lysed at day 9, and DNA
was extracted using theDNeasy kit (QIAGEN,Hilden,
Germany) according to previously published proto-
cols.19 As previously described,20 100 ng DNA was
used for MLPA, and chromosomal alterations were
compared with the patient tumor as displayed in
Table 2.
Drug Cytotoxicity Assays
UM cell lines 92.1 and MM66 were seeded at 5000,
7500, and 10,000 cells/well inULAplates and grown for
4 days to form compact spheroids. The 92.1 andMM66
UM cells were also plated into 2D, flat-bottomed, 96-
well plates at a density of 10,000 and 15,000 cells/well,
respectively, for 24 hours to reach 70% confluence. For
drug testing in both 2D and 3D, either doxorubicin
or the MEK inhibitor selumetinib was added at doses
between 0.5 and 10 μg/ml and between 0.03 and 30
μM, respectively, 24 hours after plating the cells in 2D,
as well as on day 4 of spheroid formation, following
imaging of each spheroid. The spheroids were imaged
and both 2D and 3D cultures were assessed for cell
viability 48 hours after drug addition, as described
below.
Cell Viability Assay
Cell viability was assessed in both 2D and 3D
cultures using the CellTiter-Glo 3D Cell Viability
Assay (Promega) according to the manufacturer’s
instructions using black opaque-walled multi-well
plates suitable for luminescence measurements. In
brief, 50 μl medium was removed from each well, and
50 μl CellTiter-Glo 3D was added. All procedures
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Figure1. Representative 3D spheroids ofUMcell lines seededat 5000, 7500, and10,000 cells perwell at days 4, 7 and10with corresponding
spheroid cross-sectional area measurements (4× magnification; n ≥ 6). UM cell lines (A) 92.1, (B) MP46, (C) OMM1, (D) OMM2.5, (E) MM66,
and (F) MP41. Data are mean ± SD.
were performed at room temperature. The mixture was
pipetted up and down for 30 seconds and assessed
microscopically for complete lysis of the spheroid/cells
before transferring to a black opaque-walled multi-well
plate and incubating on a shaker in the dark for 5
minutes. After a further 25-minute incubation in the
dark, luminescence was recorded using a Spark plate
reader (Tecan Trading AG, Männedorf, Switzerland).
Results
Generation of PUM and UM Cell Line
Spheroids
Use of the ULA plate methodology resulted in
both PUM and UM cell lines successfully forming
spheroids. Spheroids that formed from different PUM
and UM cell lines were of varying compactness, size,
and density, as described below.
Cell Lines
All UM cell lines tested successfully formed
spheroids (Fig. 1). Cell line spheroids varied in
compactness, with 92.1, OMM2.5, and MP46 cells
forming small, tightly packed aggregates that could
be easily manipulated by day 4. In contrast, MP41
and OMM1 cells formed loose aggregates, even at
day 10, which were difficult to technically manipulate
further, possibly due to limited cell-to-cell interaction.
MM66 cells formed small spheroids of intermediate
compactness. Each cell line differed in spheroid size
between days 4 and 10, as measured by cross-sectional
area, reflective of proliferation and compactness
(Fig. 1). MP41 and OMM1 showed the greatest cross-
sectional area (i.e., formed the largest spheroids) at
all plating densities and time points, whereas MP46
and OMM2.5 produced small, dense spheroids. 3D
spheroids formed by 92.1 and MM66 cells were inter-
mediate in terms of cross-sectional area at the time
points and plating densities examined; 92.1 had ruffle-
like edges, which have been suggested by others to
be associated with proliferating cells at the spheroid
edge.21 The 92.1, OMM1, and OMM2.5 cells demon-
strated a lag phase in spheroid growth, possibly due
to continued compacting of cells, with a significant
increase in spheroid cross-sectional area occurring for
92.1 and 0MM2.5 spheroids only by day 10 when
compared with day 4 at all plating densities (P < 0.01,
t-test). MM66 and MP41 spheroids demonstrated an
initial growth phase up to day 7, which was followed
by a reduction or stabilization of spheroid size by day
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Figure 2. Representative 3D spheroids of PUM cells seeded at 2000, 4000, 8000, and 16,000 cells per well at days 3, 6 and 9 with corre-
sponding spheroid cross-sectional area measurements (4× magnification; n = 3). PUM cells (A) S121, (B) S104, (C) S093, (D) S143, (E) S084,
and (F) S119. Data are mean ± SD.
10, reflective of compaction occurring at this later time
point. Statistically significant growth between day 4
and day 10 was only observed when MM66 and MP41
cells were plated at 5000 cells/well. MP46 cells showed
no significant alteration in spheroid size between days
4 and 10 at any of the plating densities (P > 0.01, t-
test), possibly due to the long doubling time of these
cells (∼110 hours).
These spheroid characteristics were not associated
with cell line tissue of origin (i.e., liver metastasis,
subcutaneous metastasis, or primary ocular tumor)
nor were there associations with cell morphology (i.e.,
spindle or epithelioid in shape) or the genetic profile of
UM cells.
Primary UM
All PUM samples were successfully cultured in 2D
for a single passage; however, three out of nine samples
(S145, S006, and S082) then failed to grow and form
3D spheroids when added to ULA plates at varying
cell densities. The histological and genetic character-
istics of the nine samples are shown in Table 2, and
there were no obvious morphological or genetic differ-
ences in the characteristics of the samples to explain
why some formed spheroids and others did not. As seen
with the UM cell lines, the PUM spheroids that formed
from cells isolated from different tumors (S121, S093,
S084, S104, S143, and S119) varied in shape, size, and
compactness, despite being plated at similar cell densi-
ties (Fig. 2). In general, PUM at early time points and
low seeding densities (2000 or 4000 cells) formed loose
aggregates. Spheroid cross-sectional area was greatest
at a density of 16,000 cells/well compared with 2000
cells/well on all days, as would be expected, but in
general PUM spheroids, even at the highest plating
density, were smaller than those formed by UM cell
lines at similar time points and lower plating densi-
ties. Five of the six PUM samples (S121, S093, S084,
S104, and S119) formed compact spheroids by day 9
(similar to 92.1, OMM2.5, and MP46 cells); however,
the morphological features of S119 suggest that this
was concomitant with some cell death. These spheroids
could be further manipulated for fixation and IHC
staining while retaining their structure. A single sample
(S143) continued to grow as loosely packed cells similar
to MM66 and MP41 UM cell lines. This was visible
morphologically at all plating densities; however, S143
could not be handled for fixation and downstream
applications.
To determine whether there was genetic drift
between the spheroids and the original sampled tumor
tissue, MLPA was undertaken from both the origi-
nal patient tissue and pooled PUM spheroids from
S121, S093, S084, S104, and S119 at day 9. MLPA
showed that the PUM spheroids retained the same
CNVs compared to the PUM, with the exception of
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Table 3. Comparison of Histological and Genetic Characteristics of PUM Tissue and 3D Spheroid
PUM Cell Type Macrophages nBAP1 Chr1 Chr3 Chr6p Chr6q Chr8p Chr8q
S084 Patient tumor Epithelioid Mild Negative L L N N N N
3D spheroid Epithelioid Present Negative NA NA NA NA NA NA
S093 Patient tumor Spindle Mild Positive N N G L N G
3D spheroid Spindle Present Positive N N G L N G
S104 Patient tumor Mixed NA NA N N N N N N
3D spheroid Spindle Present Positive N N N N N N
S119 Patient tumor Mixed Mild Positive N N G N N N
3D spheroid Spindle Present Positive N N G N N N
S121 Patient tumor Mixed Mild Negative L L G L N N
3D spheroid Spindle Present Negative N L N L N G
nBAP1, nuclear BAP1; L, loss; N, normal; G, gain; NA, not assessed.
Figure 3. Immunohistochemistry of 3D primary UM spheroids stained with various antibodies (20× magnification). (A) PUM enucleation
S121 stained for H&E, MelA, Ki67, BAP1, and CD68; (B) PUM endoresection S104 stained for H&E, MelA, Ki67, BAP1, and CD68; (C) PUM
enucleation S093 stained for H&E, MelA, Ki67, BAP1, and CD68.
S121 in which chr6p and chr8q status differed from
its counterpart PUM (Table 3). UM cell phenotype,
nBAP1 status, and presence/absence of macrophages
were all concordant between the PUM and the corre-
sponding 3D spheroid at day 9 for cells plated at 8000
cells per well (Fig. 3, Table 3) and for all other plating
densities analyzed (data not shown). Figure 3 shows
representative IHC images from three PUM samples
(S121, S104 and S093) of increasing cross-sectional
area at day 9 when plated at 8000 cells per well, with
mean± SDof 108411.5± 15012.3 μm2, 227550± 7050
μm2, and 376890.5± 29881.3 μm2, respectively. Of note
is the clear necrotic core observed in S093. This may
be due to the proliferative nature of the cells in this
sample as evidenced by numerous Ki67-positive cells
at the periphery, which are largely absent in S121 and
S104.
Drug Cytotoxicity Assays
Studies have previously shown that differing drugs
will induce changes in spheroid morphology charac-
teristic of the drug and its mechanism of action.22–24
We selected doxorubicin (topoisomerase 2 inhibitor), a
commonly used cancer chemotherapeutic with autoflu-
orescence properties that can be used to observe
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Figure 4. Drug cytotoxicity assays of 92.1 and MM66 UM cell line 3D spheroids treated with doxorubicin and selumetinib. Representa-
tive images of the spheroids from pre-dosing (day 4) and 48 hours after dosing (day 6) are shown (4× magnification; n = 6). Cell viability
was assessed using the CellTiter-Glo 3D Cell Viability Assay. (A) 92.1 and doxorubicin; (B) 92.1 and selumetinib; (C) MM66 and doxorubicin;
(D) MM66 and selumetinib. Data are mean ± SD. Values significantly different (P < 0.01, t-test) from control (doxorubicin) or 0.1% DMSO
(selumetinib) are denoted with # for 2D and * for 3D.
drug penetration throughout spheroids, and selume-
tinib as a targeted small molecule MEK inhibitor,
previously used in clinical trials to treat metastatic
UM with mixed results.25,26 Both 92.1 and MM66
UM cell lines were chosen to represent a primary
andmetastatic tumor phenotype, respectively, and they
showed compacted cores at day 4 with visibly prolifer-
ating cells at the periphery of the spheroid. In addition,
the differing growth characteristics of these two cell
lines were representative of that observed in the PUM
samples.
Following a 48-hour exposure, doxorubicin was
shown to penetrate through both 92.1 and MM66
spheroids at higher concentrations (≥5 μg/ml). This
resulted in dispersion and disaggregation of the cells
with increased cross-sectional area of the spheroids in
both cell lines (Figs. 4A, 4C). Increasing doxorubicin
concentrations were accompanied by significantly (P
< 0.01, t-test) decreased adenosine triphosphate (ATP)
levels and hence spheroid cell viability. For 92.1, this
was first seen at 0.5 μg/ml with a 31% reduction in
viability; for MM66, at 1.0μg/ml with a 54% reduction
in viability when compared with the untreated control
(Figs. 4A, 4C). The highest concentration of doxoru-
bicin tested (10 μg/ml) reduced spheroid cell viability by
≥99% in both cell lines when compared with untreated
control. Similar dose–response curves were observed
for 92.1 and MM66 cells treated with doxorubicin in
2D culture (Figs. 4A, 4C).
Selumetinib caused a decrease in spheroid cross-
sectional area at drug concentrations ≥ 0.03 μM for
92.1 spheroids, and ≥ 0.3 μM for MM66 spheroids
(Figs. 4B, 4D). This was further supported by the
significant (P < 0.01, t-test) decrease in ATP measure-
ments and hence spheroid cell viability at these drug
concentrations when compared with the 0.1% dimethyl
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sulfoxide (DMSO) control. For 92.1, there was a 45%
reduction in spheroid cell viability and for MM66 a
50% reduction in spheroid cell viability when compared
with the 0.1% DMSO control. At the highest concen-
tration of selumetinib tested, 92.1 spheroid cell viabil-
ity was reduced by 81.5% and MM66 by 62.5% when
compared with the 0.1% DMSO control. The effect
of selumetinib on 2D-cultured 92.1 cells were similar
to those observed in 3D; however, for MM66 cells,
selumetinib had no effect on reducing cell viability
in 2D culture (Fig. 4D). Although it was not possi-
ble in this study to examine the penetration of 3D
spheroids by selumetinib, the morphology of 92.1 and
MM66 spheroids following treatment with this drug
suggested that, unlike doxorubicin, which penetrated
to the core of the spheroid, selumetinib acted predom-
inantly on the cells close to the surface of the spheroid,
leaving an intact viable cell core 48 hours after treat-
ment. The ATP signal at the highest selumetinib
concentration, compared to doxorubicin at the highest
concentration, is suggestive of this remaining cellular
core.
The effects of doxorubicin in 92.1 and MM66
spheroids formed from an initial plating density of
7500 cells/well (Fig. 4) were similar when cells were
plated at 5000 and 10,000 cells/well (Supplementary
Figure S1). This demonstrates that drug penetration
was unaffected by increasing spheroid diameter in 92.1
andMM66 cells up to a maximum of 1144.46± 288.62
μm and 1695.28± 128.32 μm, respectively, as examined
in this study.
Discussion
In this study, we describe details of PUM cell-
derived spheroids and define the methods for generat-
ing 3D spheroids from both UM cell lines and PUM
for use in downstream drug screening assays. Morpho-
logical, immunohistochemical, and genetic analyses
of fixed PUM spheroids confirmed that they retain
the histological and genetic characteristics of the
primary tumor and as such are an important first
step in treatment personalization. Development of a
drug discovery pipeline has been initiated to measure
endpoints such as spheroid cross-sectional area and
to use viability endpoint assays to measure ATP
synthesis.
Traditionally, modeling of cancer cell biology in
an in vitro setting has been confined to 2D cell
culture models, which have been used to analyze a
range of cell behaviors (e.g., proliferation, migration,
invasion) in both drug-treated and untreated cells.
However, more recently, researchers have been devel-
oping 3D cell culture models that incorporate the
physiological TME, allowing them to more closely
recapitulate tumor characteristics, with the aim of
providing more translatable results.1,27 To establish
a 3D UM spheroid model in this study, a range
of reported techniques, including hanging drop and
poly(2-hydroxyethyl methacrylate) matrix suspension
have been tested.28 We established that the use of ULA
plates seeded with a range of cell densities provided
the most robust and reproducible technique to gener-
ate uniform-sized spheroids for each UM cell line
and PUM cells.29 All cell lines ultimately produced
uniform-sized spheroids; however, it is important to
note that the spheroids differed among each UM cell
line and PUM cells, in terms of overall size (measured
by cross-sectional area), compactness, and density.
Further, the time taken to undergo the spheroid cellu-
lar reorganization varied from 4 to 7 days for four UM
cell lines (92.1, MP46, OMM2.5, and OMM1), and up
to 10 days for two others (MM66 and MP41). This
variability in the formation of spheroids by UM cell
lines cannot be explained by their underlying genetic
profile but is important to consider when design-
ing drug screening studies, such that several param-
eters, including a minimum cross-sectional area and
cell density, are defined as the point at which drug
testing should commence. From our initial data, we
suggest a minimum cross-sectional area of 1 × 106
μm2. Although we were unable to estimate cell density,
future studies will use an algorithm present on the
Cytation 5 (BioTek UK, Swindon, UK) to determine
this. Ultimately, this may require the slower growing
cells (e.g.,MP46) or cells that compact less rapidly (e.g.,
MP41, MM66) to be plated at higher densities and/or
tested at later time points.
Most of the UM cell lines could be removed from
the ULA plates for downstream analyses, with the
exception of MP41 and OMM1 spheroids, which
disaggregated with pipetting. Such tumor spheroid
disaggregation on removal from ULA wells has been
reported by other investigators.30,31 It is unclear why
this occurs, but it may be caused by differences
in extracellular matrix deposition or by the inter-
cellular adhesions between tumor cells. Ivanov and
Grabowska30 have cleverly designed agarosemolds that
do not require the tumor spheroids to be removed
from the wells for histological embedding, sectioning,
or staining; instead, spheroid tissue microarrays are
created, allowing for high-throughput analysis of large
3D tumor cell spheroid sample sets. We are currently
trialing such molds to examine numerous UM cell line
spheroids in parallel in order to undertake multidrug
screening.
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Also novel in the current study is the description
of the successful generation of UM spheroids derived
from PUM samples, with morphological, immunohis-
tochemical, and genetic characteristics representative
of the original patient tumor. In general, the PUM
spheroids generated had a lowproliferative index, apart
from S093, which also showed central necrosis and
contained admixed macrophages, which are present
in both PUM32 and metastatic UM33 and are associ-
ated with a poor outcome.34 Although the largest
and least compact of the PUM spheroids was formed
by the sample with dense macrophage content, any
correlation between this feature and spheroid growth
characteristics was not possible to determine in the
current study due to the small numbers analyzed.
Admixedmacrophages and other cells within the PUM
are also likely to influence drug uptake and/or drug
response as shown in colon cancer spheroids.35 Fresh
PUM samples are relatively difficult to obtain and
should be harvested soon after surgery; when they
have been cultured, PUM cells show changes in cellu-
lar morphology and molecular characteristics within
a few passages.36 We recommend the generation of
PUM spheroids from early passage cells with associ-
ated histological and genetic work-ups, and yet note
that ∼30% of PUM may not form 3D spheroids. The
reasons for this remain unclear, but we speculate that
this could be due to specimens with a very low prolifer-
ation rate that in general also fail to grow after the first
passage in 2D-culture due to senescence. This clearly
has implications for personalizedmedicine, and further
studies are necessary to determine whether UM cells
isolated from metastatic lesions have a similar failure
rate in 3D culture.
Two other interlinked features of the UM spheroids
that we examined in this study were drug penetrance
and efficacy, which we investigated through the use
of two drugs previously administered in the context
of metastatic UM—namely doxorubicin and selume-
tinib. The two drugs have differing modes of action;
doxorubicin acts by intercalating with DNA to
cause DNA damage, and selumetinib is an ATP-
independent inhibitor of mitogen-activated protein
kinase/extracellular signal-regulated kinase 1/2.37,38
For both doxorubicin and selumetinib, entry into the
cell is influenced by plasma membrane lipid compo-
sition. Doxorubicin and selumetinib have molecular
weights of 543.5 and 457.7, respectively, suggesting that
the differences in cell viability observed for the two
drugs is not merely due to their ability to penetrate the
spheroid. Moreover, similar effects of doxorubicin and
selumetinib were observed in spheroids of varying size.
Instead, we suggest that the mixture of growing and
quiescent cells in differing metabolic states that likely
exist within the larger spheroids will affect drug efficacy
in a manner more akin to that observed in vivo.
The aspect of drug penetration was specifically
assessed by profiling doxorubicin, which is known to
autofluoresce and act as a biocompatible fluorophore
with an absorption peak around 488 nm of Ar+
laser.25 The penetration of doxorubicin into the UM
spheroids was easily observed at the higher concentra-
tions, which has previously been seen in other cancer
spheroids, such as breast.27 Although it was not possi-
ble to fully assess the degree of penetrance of selume-
tinib, cell viability at the periphery of the 92.1 and
MM66 spheroids appeared reduced upon imaging; this
was confirmed by use of the CellTiter-Glo 3D Cell
Viability Assay, which assessed the viability of all cells
within the spheroid. This effect of spheroid cell killing
occurring at the periphery has recently been reported
in squamous cell carcinoma spheroids treated with a
microtubule-inhibiting small molecule that was able to
slowly work inward to cause the death of cells within
the central core.39 Methods used to increase drug
penetrance into spheroids have also been described,
including electrochemotherapy.40
With respect to drug efficacy, studies have shown
that in 2D cell culture systems potency is enhanced
when compared with 3D models,21 such that the
predicted clinical efficacy in patients is often overes-
timated.1 Interestingly, in our study, doxorubicin had
similar effects on 92.1 and MM66 cells grown in 2D or
3D culture irrespective of spheroid parameters such as
compactness, growth rate, or cross-sectional area. The
results for selumetinib in the MM66 cell line, however,
were somewhat unexpected, as selumetinib was more
effective in MM66 cells in 3D than in 2D when ATP
synthesis was assessed. One possible explanation for
this could be more rapid proliferation of the unaffected
cells in a 2D setting that is not seen with the more
slowly cycling cells in a 3D spheroid. Measuring recov-
ery of cellular growth in 3D spheroid models will,
therefore, be of importance when considering residual
tumor burden and drug resistance.
Goncalves et al.8 also reported the effects of another
MEK inhibitor, trametinib, in 3D spheroids of UM
cell lines placed in a collagen matrix. They observed an
increase in the number of dead cells at the edge of the
spheroid following treatment with a single concentra-
tion of trametinib, as measured by propidium iodide
staining. Shaughnessy et al.9 described the forma-
tion of multiple spheroids when UM cell lines were
placed in a Matrigel matrix, and they used this method
to screen the effects of the calcium channel blocker
amlodipine. In this latter study, spheroids of differing
sizes were produced and then randomly sampled for
measurement in the presence or absence of the drug.
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Cell surface interactions with extracellular matrices are
also likely to contribute to drug efficacy and penetra-
tion, factors that were not discussed in these papers
but which must be considered when developing assay
systems for drug discovery and screening.
In conclusion, we have described optimal conditions
for the reproducible production of 3D spheroids of
uniform size from UM cell lines and PUM samples,
as well as their use in drug screening assays. We are of
the opinion that the panel of UM cell lines examined
in this study can be used to mimic many aspects
of the heterogeneous in vivo tumor cell population,
such as proliferation, oxygen and nutrient gradients,
and cellular interactions when grown in a 3D culture
as compared with monolayer cultures. In particular,
monitoring of 3D phenotypic parameters, such as
spheroid size, shape, and internal features, combined
with a variety of endpoint assays, will allow the
outcomes of drug action at a multicellular level to
be more accurately evaluated. Further development
of 3D culture methods may involve incorporation of
multiple cell types that mimic the metastatic TME
and the use of hydrogels as scaffolds to encapsulate
the cells or to serve as mechanical and biochemi-
cal cues that more accurately represent the composi-
tion of the tumor extracellular matrix and the seques-
tration of biomolecules within.41,42 Development of
these methodologies is ongoing for many tumor types,
including UM, and requires a detailed understand-
ing of the TME composition, stiffness, and surface
chemical properties. Although these more complex
models will ultimately allow a better understanding of
UM biology and drug efficacy, their development is
time consuming and expensive and poses numerous
challenges in terms of microscopy and assay measure-
ments. New imaging modalities such as Cytation 5/7
(BioTek) and Incucyte S3 (Essen Bioscience, Hertford-
shire,UK) offer live imaging of spheroidswith software
packages and complex algorithms for powerful analysis
of cellular events in scaffold-free and scaffold-based 3D
cell culture models. The use of well-defined 3D models
of UM cell lines and ultimately metastatic UM patient
material will lead us closer to the goal of personalized
medicine.
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